文献速递甲状腺疾病

分化型甲状腺癌咽后淋巴结转移的管理

Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2020-02-07

本研究回顾性分析了1999至2018年间本机构65例分化型甲状腺癌咽后淋巴结转移患者,其中82%为复发病例;患者分为观察组25例、非手术治疗组13例和手术切除组27例。咽后淋巴结转移的大小可预测手术与观察的选择(p < 0.001)。全队列5年局部控制率为92%,5年和10年无远处转移概率分别为72%和62%,5年和10年疾病特异性生存率分别为93%和81%。

要点

  • 分化型甲状腺癌咽后淋巴结转移多数(82%)表现为复发病灶。
  • 小体积且无进展的咽后淋巴结转移患者可能适合观察,而大或进展的转移可能需要手术。
  • 咽后淋巴结转移的存在似乎与侵袭性疾病相关。

核心结论

  • 分化型甲状腺癌相关咽后淋巴结转移在多数患者中表现为复发性疾病,其存在似乎与侵袭性疾病相关。
  • 作者认为,选择性的小体积且无进展的咽后淋巴结转移患者可能适合观察,而大或进展的咽后淋巴结转移可能需要手术。

研究设计与样本

  • 本研究为本机构1999年至2018年间诊断的分化型甲状腺癌相关咽后淋巴结转移患者的回顾性研究,通过影像学和病理学报告中的关键词检索识别患者。
  • 共识别65例患者,根据咽后淋巴结转移的管理方式分为观察组、非手术治疗组和手术切除组,采用Kaplan-Meier法计算局部控制率、疾病特异性生存率和无远处转移概率。

主要发现

  • 65例患者中,53例(82%)的咽后淋巴结转移为复发性疾病的表现。
  • 25例(38%)接受观察,13例(20%)接受非手术治疗(放射性碘、外照射放疗和/或全身治疗),27例(42%)接受手术切除。
  • 观察组所有患者咽后淋巴结转移稳定,其中大多数(80%)在观察期间(中位28个月)保持<1.5 cm。
  • 非手术治疗组13例中,3例接受放射性碘治疗,7例接受外照射放疗,3例仅接受全身治疗。
  • 手术组咽后淋巴结转移中位最大直径为2.0 cm(范围0.8-4.2 cm),咽后淋巴结转移大小可预测手术与观察的选择(p < 0.001)。

关键数值与推荐

  • 全队列5年和10年无远处转移概率分别为72%和62%。
  • 全队列5年和10年疾病特异性生存率分别为93%和81%。
  • 5年局部咽后淋巴结转移控制率为92%。

临床怎么用

  • 作者认为,选择性的小体积且无进展的咽后淋巴结转移患者可能适合观察。
  • 作者认为,大或进展的咽后淋巴结转移可能需要手术。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Retropharyngeal lymph node metastases (RPMs) from differentiated thyroid carcinoma (DTC) are rare. Treatment includes surgical resection, radioactive iodine (RAI) therapy, or external beam radiation therapy (EBRT). The objective of this study was to describe our experience in the management of DTC-associated RPMs. Methods: Patients diagnosed with a DTC-associated RPM from 1999 to 2018 were identified at our institution, using key search terms in imaging and histology reports. Patient and tumor characteristics were recorded, and patients were grouped according to RPM management: observation, nonsurgical treatment, or surgical resection. The estimated rates of local RPM control, disease-specific survival (DSS), and distant metastasis-free probability (DMFP) were calculated by using the Kaplan-Meier method. Results: Of the 65 patients identified, 53 (82%) had an RPM as a manifestation of recurrent disease. Twenty-five patients (38%) underwent observation, 13 (20%) received nonsurgical treatment (RAI, EBRT, and/or systemic therapy), and 27 (42%) underwent surgical resection. In the observation cohort, all patients had a stable RPM, which in the majority (80%) of cases remained <1.5 cm during the period of observation (median 28 months). Of the 13 patients in the nonsurgical treatment cohort, 3 received RAI therapy, 7 received EBRT, and 3 received systemic therapy only. In the surgical cohort, the median RPM maximum diameter was 2.0 cm (range 0.8-4.2 cm). The size of the RPM was predictive of surgical resection versus observation (p < 0.001). A transcervical approach was employed in 19 patients, and a transoral approach was used in 8 patients. The 5-year rate of local RPM control was 92%. For the whole cohort, the 5- and 10-year DMFP were 72% and 62%, respectively; the 5- and 10-year DSS were 93% and 81%, respectively. Conclusions: DTC-associated RPMs manifest as recurrent disease in the majority of patients. Select patients with a small-volume and nonprogressive RPM may be suitable for observation, whereas surgery is likely warranted in large or progressing RPMs. In general, the presence of an RPM from DTC appears to be associated with aggressive disease.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Harries V, McGill M, Tuttle RM, et al. Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. Thyroid. 2020. PMID: 31910129. doi:10.1089/thy.2019.0359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。